PEDIATRICS Vol. 91 No. 5 May 1993, pp. 1001-1002
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation

Controversies Concerning Vitamin K and the Newborn

Vitamin K Ad Hoc Task Force

Vitamin K deficiency may cause unexpected bleeding (0.25% to 1.7% incidence) during the first week of life in previously healthy-appearing neonates (classic hemorrhagic disease of the newborn [HDN]). The efficacy of neonatal vitamin K prophylaxis (either oral or parenteral) in the prevention of classic HDN is firmly established. It has been the standard of care since the recommendation by the Committee on Nutrition was adopted as policy by the American Academy of Pediatrics in 19611

Late HDN, a syndrome defined as unexpected bleeding due to severe vitamin K deficiency in infants aged 2 to 12 weeks, occurs primarily in exclusively breast-fed infants who have received no or inadequate neonatal vitamin K prophylaxis. In addition, infants who have intestinal malabsorption defects (cholestatic jaundice, cystic fibrosis, etc) may also present with late HDN. The rate of late HDN (often manifested by sudden central nervous system hemorrhage) ranges from 4.4 to 7.2 per 100 000 births based on reports from Europe and Asia. When a single dose of oral vitamin K has been used as neonatal prophylaxis, the rate has decreased to 1.4 to 6.4 per 100 000 births. Parenteral neonatal vitamin K prophylaxis prevents the development of late HDN, with the rare exception of infants with severe malabsorption syndromes. Oral regimens that have a similar efficacy as parenteral vitamin K in prevention of late HDN include the repeated administration of oral vitamin K1 (Germany) or K2 (Japan) at birth, 1 week, and 2 to 4 weeks.

In 1990 Golding et al2 reported a study of a 1970 birth cohort in Britain in which they noted an unexpected association between childhood cancer and pethidine given in labor and the neonatal administration of vitamin K. Subsequently, Golding and others3 conducted a case-control study designed to examine the risk of cancer associated with intramuscular vitamin K administration among infants born in two hospitals in Avon between 1965 and 1987 and diagnosed with cancer between 1971 and 1989.

Submitted on February 1, 1993
Accepted on February 3, 1993


The following policy statement is a revision:

Controversies Concerning Vitamin K and the Newborn

Pediatrics 112: 191-192. [Full Text]



This article has been cited by other articles:


Home page
 CLIN PEDIATRHome page
M. W. Thomas and B. M. Gebara
Difficulty Breathing
Clinical Pediatrics, June 1, 2004; 43(5): 499 - 502.
[PDF]

Home page
 PediatricsHome page
Committee on Fetus and Newborn
Controversies Concerning Vitamin K and the Newborn
Pediatrics, July 1, 2003; 112(1): 191 - 192.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
E Hey
Vitamin K--what, why, and when
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2003; 88(2): F80 - F83.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child. Fetal Neonatal Ed.Home page
S P Pereira, M J Shearer, R Williams, and G Mieli-Vergani
Intestinal absorption of mixed micellar phylloquinone (vitamin K1) is unreliable in infants with conjugated hyperbilirubinaemia: implications for oral prophylaxis of vitamin K deficiency bleeding
Arch. Dis. Child. Fetal Neonatal Ed., March 1, 2003; 88(2): F113 - F118.
[Abstract] [Full Text] [PDF]

Home page
 PediatricsHome page
D. Kumar, F. R. Greer, D. M. Super, J. W. Suttie, and J. J. Moore
Vitamin K Status of Premature Infants: Implications for Current Recommendations
Pediatrics, November 1, 2001; 108(5): 1117 - 1122.
[Abstract] [Full Text] [PDF]

Home page
 Arch. Dis. Child.Home page
F. R Greer, S. P Marshall, R. R Severson, D. A Smith, M. J Shearer, D. G Pace, and P. H Joubert
A new mixed micellar preparation for oral vitamin K prophylaxis: randomised controlled comparison with an intramuscular formulation in breast fed infants
Arch. Dis. Child., October 1, 1998; 79(4): 300 - 305.
[Abstract] [Full Text]

Home page
 DTBHome page
Which vitamin K preparation for the newborn?
DTB, March 1, 1998; 36(3): 17 - 19.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
A. Zipursky
Vitamin K at birth
BMJ, July 27, 1996; 313(7051): 179 - 180.
[Full Text]

Home page
 NEJMHome page
M. A. Klebanoff, J. S. Read, J. L. Mills, and P. H. Shiono
The Risk of Childhood Cancer after Neonatal Exposure to Vitamin K
N. Engl. J. Med., September 23, 1993; 329(13): 905 - 908.
[Abstract] [Full Text]

Home page
 NEJMHome page
M. W. Hilgartner
Vitamin K and the Newborn
N. Engl. J. Med., September 23, 1993; 329(13): 957 - 958.
[Full Text]